Grants and Contracts Details
Description
Abstract
Epithelial-to-mesenchymal transition (EMT) causes cancer cells to switch their axis of polarity from
apical-basal to front-rear, which orients organelles and actin-based cytoskeletal structures in ways that
facilitate purposeful cancer cell motility and metastasis1. Kurie lab reported that lung adenocarcinoma
(LUAD) metastasis is EMT-dependent and that the EMT-activating transcription factor ZEB1 silences
microRNAs that target key inhibitors of the polarity axis switch2-6. These data support the general belief
that EMT-dependent metastasis is a cell-autonomous process. My new preliminary results, however,
show that ZEB1 also activates the secretion of pro-metastatic effector proteins by initiating polarized
trafficking of secretory vesicles toward the leading edge. These results, which build on findings that I
made in the laboratory of Dr. Sandra Schmid7,8, underlie my hypothesis that ZEB1 initiates polarized
secretion of pro-tumorigenic effector proteins to drive LUAD progression. We will test the hypothesis by
completing the following specific aims.
Status | Active |
---|---|
Effective start/end date | 3/12/24 → 2/28/27 |
Funding
- National Cancer Institute: $249,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.